TABLE 3.

Effect of benzimidazole ribonucleosides on laboratory and clinical isolates of HCMV

Isolate50% inhibitory concn (μM)a
BDCRB1263W94 (37°C)1263W94 (34°C)175XGCV
AD1690.4 ± 0.219.4 ± 18.63.0 ± 32.2 ± 0.54.3 ± 0.4
Towne1.2 ± 0.3>4414 ± 95.2 ± 2.57.2 ± 3.3
Davis0.6 ± 0.10.6 ± 0.2NTb1.9 ± 1.14.3 ± 0.6
Toledo1.1 ± 0.1>47 ± 72.15.3 ± 1.36.9 ± 2.3
EC1.0 ± 0.511.2 ± 11.70.93.8 ± 0.39.7 ± 5.4
CH0.44.01.13.04.3 ± 0.4
C8708/17-1-10.7 ± 0.50.2 ± 0.050.32.0 ± 1.34.3 ± 0.6
Coffman1.1 ± 0.416.5 ± 3.5113.8 ± 0.411.5 ± 5.1
C9208/3-3-10.815.9 ± 10.611.22.0 ± 0.52.2 ± 0.8
C9208/5-4-20.8 ± 0.31.30.72.32.4
  • a Values are expressed as the mean ± standard deviation of at least two plaque reduction assays.

  • b NT, not tested.